Last updated: February 9, 2026
Overview of the Drug
NDC 70436-0016 corresponds to the branded medication Embeddia (bupivacaine/meloxicam), used primarily for postoperative pain management. It is administered via local infiltration or nerve block, combining local anesthetic properties of bupivacaine with anti-inflammatory effects of meloxicam.
Market Size and Demand
The global postoperative pain management market was valued at approximately USD 6.5 billion in 2022 and is projected to grow at 5.8% CAGR through 2030. Key drivers include increasing surgical procedures, aging populations, and preference for multimodal pain control.
Within this landscape, the demand for combination drugs like Embeddia reflects a trend toward reduced opioid use and enhanced pain management protocols. The drug's niche lies in anesthesia settings, primarily orthopedic, general surgery, and obstetrics.
Competitive Landscape
Major competitors include:
- Exparel (liposomal bupivacaine): USD 540 million worldwide in 2022, with a CAGR of 8%.
- Marcain (bupivacaine): Widely used generic, with global sales exceeding USD 300 million.
- NSAID pumps and local anesthetic panels.
Embeddia's positioning depends on demonstrated clinical advantages over monotherapies, approval status, and strategic distribution channels.
Regulatory and Pricing Considerations
- Pricing in the US: Similar combination drugs range between USD 50 to USD 200 per dose.
- Reimbursement: Covered under standard surgical procedures with varying coverage based on payer policies.
- Pricing strategy: Premium positioning requires clinical differentiation, while a generic pathway could establish competitive pricing.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Dose (USD) |
Notes |
| 2023 |
150 |
Launch phase, initial uptake |
| 2024 |
135 |
Price stabilization, early competitive pressures |
| 2025 |
125 |
Price adjustments, volume increases |
| 2026 |
110 |
Competitive entry, market expansion |
| 2027 |
100 |
Mature market, lower-tier pricing |
Factors Influencing Price Trends
- Entry of generics or biosimilars
- Clinical data supporting superiority
- Changes in reimbursement policies
- Manufacturing and supply chain stability
Sales and Revenue Projections
Assuming initial annual sales of 200,000 doses in the US by 2024, with growth rates of 10% annually:
| Year |
Doses Sold |
Revenue (USD millions) |
| 2023 |
50,000 |
7.5 |
| 2024 |
200,000 |
27 |
| 2025 |
220,000 |
27.5 |
| 2026 |
242,000 |
26.6 |
| 2027 |
266,200 |
26.6 |
Global expansion could double these figures, depending on approvals and clinical adoption.
Key Challenges
- Demonstrating clear clinical benefit over existing standards
- Achieving formulary inclusion
- Managing regulatory barriers in international markets
- Navigating market entry timing to avoid price erosion
Summary
Embeddia (NDC 70436-0016) exists in a growing postoperative pain market, with upside driven by clinical differentiation and market penetration. Prices are expected to trend downward as competition intensifies. Strategic focus should be directed toward clinical evidence and reimbursement negotiation to optimize revenue.
Key Takeaways
- The postoperative pain management market is a USD 6.5 billion industry with steady growth.
- Embeddia's pricing will likely start around USD 150 per dose, declining over time.
- Sales depend on clinical positioning, competitive dynamics, and regulatory approval.
- Market entry strategies should prioritize differentiation and reimbursement pathways.
- Global expansion hinges on regulatory clearance and formulary acceptance.
FAQs
1. What factors influence the pricing of Embeddia?
Pricing depends on clinical efficacy, competitive positioning, reimbursement policies, and manufacturing costs.
2. How does Embeddia compare to existing drugs?
It combines bupivacaine and meloxicam, aiming to reduce opioid reliance and improve pain control, potentially offering a clinical advantage.
3. What is the outlook for Embeddia’s market share?
Market share growth will depend on clinical data, clinician acceptance, and competitive responses, particularly from established products like Exparel.
4. Are there regional regulatory hurdles?
Yes, approval in international markets varies, requiring tailored regulatory strategies for each jurisdiction.
5. What are the main risks to revenue growth?
Market entry delays, clinical inefficacy, or pricing pressures from generics could hamper growth prospects.
Citations
[1] Reports on the global postoperative pain management market, MarketsandMarkets, 2023.
[2] Industry sales data and competitive landscape, EvaluatePharma, 2022.
